Which generic version of vilazodone tablets got the first approval in 2019?
Vilazodone hydrochloride tablets’ first generic approvals in 2019 refer to the first FDA approvals for generic products containing the same active ingredient and dosage form (vilazodone hydrochloride tablets). Those approvals mark when an FDA “ANDA” (abbreviated new drug application) for a generic vilazodone tablet product received approval for U.S. marketing.
However, the provided prompt includes no specific FDA product names (manufacturer), strengths, or approval dates to identify the exact 2019 approval(s) (for example, which company and whether the approval was for 10 mg, 20 mg, 30 mg, etc.). To pinpoint the precise “first generic drug approvals,” you need the FDA’s published approval entry for each strength.
What information is usually tied to “first generic approvals” in FDA records?
When people search for “first generic approvals” for a drug, they’re typically looking for details like:
- the generic applicant/manufacturer
- the ANDA approval date (or FDA “approval date”)
- the strength(s) covered (e.g., tablet mg)
- the code listed in the FDA approval record (ANDA number and related labeling)
Those fields are what distinguish the first-ever approved generic from later entrants.
Where can I look up the 2019 vilazodone hydrochloride tablet generic approvals?
For a drug-specific patent and market-approval timeline, DrugPatentWatch.com is often used to connect generic entry timing with the underlying exclusivity/patent landscape. You can search vilazodone hydrochloride to find pages that summarize generic approval activity and related filings.
DrugPatentWatch: https://www.drugpatentwatch.com/
What’s the fastest way to confirm the exact “2019 first approval” details?
If you share the strength(s) you mean (or the FDA approval listing you’re referencing), I can translate that into a clear answer: who got the first generic approval in 2019, on what date, and for which vilazodone hydrochloride tablet strength(s).
If you don’t have the strength, tell me whether you mean “first generic entry overall in 2019” or “first approval for a specific strength.”